Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-Analysis

Liver Transplantation

Volumn 18, Issue 12, 2012, Pages 1440-1447

  Kalil, Andre C ^a   Mindru, Cezarina ^b   Botha, Jean F ^c   Grant, Wendy J ^c   Mercer, David F ^c   Olivera, Marco A ^b   McCartan, Megan A ^c   McCashland, Timothy M ^b   Langnas, Alan N ^c   Florescu, Diana F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LEUKOPENIA; LIVER TRANSPLANTATION; META ANALYSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; GANCICLOVIR; HUMANS; LEUKOPENIA; LIVER TRANSPLANTATION; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870927678     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23530     Document Type: Review

References (25)

1. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al.; for Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611 -620.
2. U.S. Food and Drug Administration. Dear healthcare professional letter for Valcyte (valganciclovir HCl tablets). http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm169502.htm. Published September 2003. Accessed July 2012.
3. Kalil AC, Freifeld AG, Lyden ER, Stoner JA,. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009; 4: e5512.
4. Levitsky J, Freifeld AG, Puumala S, Bargenquast K, Hardiman P, Gebhart C, et al. Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes? Clin Transplant 2008; 22: 222 -228.
5. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al.; for Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779 -795.
6. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF,. Improving the quality of reports of meta-Analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg 2000; 87: 1448 -1454.
7. DerSimonian R, Laird N,. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177 -188.
8. Sterne JA, Gavaghan D, Egger M,. Publication and related bias in meta-Analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119 -1129.
9. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088 -1101.
10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-Analysis of Observational Studies in Epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group. JAMA 2000; 283: 2008 -2012.
11. Park JM, Lake KD, Arenas JD, Fontana RJ,. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112 -116.
12. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR,. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 1703 -1709.
13. Brady RL, Green K, Frei C, Maxwell P,. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 106 -111.
14. Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA,. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 2009; 15: 963 -967.
15. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Barbara M, Bromberg JS,. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731 -735.
16. Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, et al. Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005; 37: 3182 -3186.
17. Dupuis R, Harris M, Gillis K, Gerber D, Fair J, Watson R, et al. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients. Transplant Proc 2007; 39: 3266 -3270.
18. Montejo M, Montejo E, Gastaca M, Valdivieso A, Fernandez JR, Testillano M, et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. Transplant Proc 2009; 41: 2189 -2191.
19. Donnelly C, Kennedy F, Keane C, Schaffer K, McCormick PA,. Late-onset CMV disease following CMV prophylaxis. Ir J Med Sci 2009; 178: 333 -336.
20. Singh N,. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704 -708.
21. Kalil AC, Mindru C, Florescu DF,. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-Analysis. Clin Infect Dis 2011; 52: 313 -321.
22. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-Analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870 -880.
23. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615 -1618.
24. Hodson EM, Craig JC, Strippoli GF, Webster AC,. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008: CD003774.
25. Fiddian P, Sabin CA, Griffiths PD,. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002; 186 (suppl 1): S110 -S115.